연구동향 분석

The Pathogenic Roles of S100A8, S100A9 and Their Interaction with SFPQ in Parkinson’s Disease = 파킨슨병에서 S100A8 및 S100A9 의 병원성 역할과 SFPQ 와의 상호 작용

Ayesha Kashif 2022년

논문상세정보
인용/피인용
' The Pathogenic Roles of S100A8, S100A9 and Their Interaction with SFPQ in Parkinson’s Disease = 파킨슨병에서 S100A8 및 S100A9 의 병원성 역할과 SFPQ 와의 상호 작용' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • SFPQ
  • apoptosis
  • mislocalization
  • parkinson’s disease
  • s100a8
  • s100a9
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
602 0

0.0%

' The Pathogenic Roles of S100A8, S100A9 and Their Interaction with SFPQ in Parkinson’s Disease = 파킨슨병에서 S100A8 및 S100A9 의 병원성 역할과 SFPQ 와의 상호 작용' 의 참고문헌

  • Widespread expression of MRP8 and MRP14 in human cerebral malaria by microglial cells .
    Schluesener HJ , Kremsner PG , Meyermann R. 96 ( 6 ) : 575 ? 580 . [1998]
  • Upregulated expression of S100A8 in mice brain after focal cerebral ischemia reperfusion .
  • The structure of human SFPQ reveals a coiled-coil mediated polymer essential for functional aggregation in gene regulation .
  • The pro-apoptotic effects of S100A8 and S100A9 in human monocytic leukemia cells
    Kim IS , Lee JS . 24 ( 2 ) : 134 ? 137 . [2018]
  • The many faces of α- synuclein : from structure and toxicity to therapeutic target
  • The emerging role of the RNAbinding protein SFPQ in neuronal function and neurodegeneration
    Lim YW , James D , Huang J , Lee M. 21 ( 19 ) : 7151 . [2020]
  • The burden of Parkinson s disease : a worldwide perspective
    Rocca WA 17 ( 11 ) : 928 ? 929 [2018]
  • The RNA/DNAbinding protein PSF relocates to cell membrane and contributes cells sensitivity to antitumor drug , doxorubicin
  • The Preventive and Therapeutic Effects of Intravenous Human Adipose- Derived Stem Cells in Alzheimer s Disease Mice
  • Targeting mitochondrial calcium pathways as a potential treatment against Parkinson s disease
  • Structural basis of the zinc-induced cytoplasmic aggregation of the RNA-binding protein SFPQ
  • SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells
  • S100a9 Knockdown Decreases the Memory Impairment and the Neuropathology in Tg2576 Mice , AD Animal Model
  • S100A8 and S100A9 secreted by allergens in monocytes inhibit spontaneous apoptosis of normal and asthmatic neutrophils via the Lyn/akt/ERK pathway
    Kim IS , Lee JS . 49 ( 2 ) : 128 ? 134 . [2017]
  • Role of DJ-1 in the mechanism of pathogenesis of Parkinson s disease
  • Reactive oxygen species ( ROS ) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun Nterminal kinase and inhibited by p38 mitogen-activated protein kinase ( MAPK ) activation
  • Quantitative Proteomics Reveals Dynamic Interaction of c-Jun Nterminal Kinase ( JNK ) with RNA Transport Granule Proteins Splicing Factor Proline- and Glutamine-rich ( Sfpq ) and Non-POU Domaincontaining Octamer-binding Protein ( Nono ) during Neuronal Differ
  • Proteomics analysis of blood serums from Alzheimer s disease patients using iTRAQ labeling technology
  • Prevalence and duration of non-motor symptoms in prodromal Parkinson s disease
  • Post-transcriptional gene silencing mediated by microRNAs is controlled by nucleoplasmic Sfpq
  • Phosphorylation-Dependent Regulation of PSF by GSK3 Controls CD45 Alternative Splicing
    Heyd F , Lynch KW 40 ( 1 ) : 126 ? 137 . [2010]
  • Parkinson s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration
  • Oxidative stress in the aging substantia nigra and the etiology of Parkinson s disease
    Trist BG , Hare DJ , Double KL 18 ( 6 ) : e13031 [2019]
  • Nuclear Relocalization of the Pre-mRNA Splicing Factor PSF during Apoptosis Involves Hyperphosphorylation , Masking of Antigenic Epitopes , and Changes in Protein Interactions
  • Neutrophil proteome shifts over the myocardial infarction time continuum
  • Neuroinflammation in synucleinopathies
    Lim S , Chun Y , Lee JS , Lee S. 26 ( 3 ) : 404 ? 409 . [2016]
  • Neuroinflammation and protein pathology in Parkinson s disease dementia
  • Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing .
  • MDS clinical diagnostic criteria for Parkinson s disease
  • Loss of Sfpq Causes Long-Gene Transcriptopathy in the Brain
  • Long-term beneficial effects of hematopoietic growth factors on brain repair in the chronic phase of severe traumatic brain injury
  • Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex
  • Long Noncoding RNA NEAT1-Dependent SFPQ Relocation from Promoter Region to Paraspeckle Mediates IL8 Expression upon Immune Stimuli
  • Lessons from tau-deficient mice
  • LRRK2 contributes to monocyte dysregulation in Parkinson s disease
  • Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALS
  • Intrinsically aggregation-prone proteins form amyloidlike aggregates and contribute to tissue aging in Caenorhabditis elegans
  • Inherent oxidative stress in the Lewis rat is associated with resistance to toxoplasmosis .
    Witola WH , Kim CY , Zhang X . 85 ( 10 ) : e00289-17 . [2017]
  • Inflammatory S100A9 and S100A12 proteins in Alzheimer s disease
  • Extracellular signal-regulated kinase : a regulator of cell growth , inflammation , chondrocyte and bone cell receptormediated gene expression
    Lu N , Malemud CJ . 20 ( 15 ) : 3792 . [2019]
  • Evolving basic , pathological and clinical concepts in PD
    Kalia L V , Lang AE . 12 ( 2 ) : 65 ? 66 [2016]
  • Effect of S100A8 and S100A9 on expressions of cytokine and skin barrier protein in human keratinocytes
  • Comprehensive assessment of PINK1 variants in Parkinson s disease
  • Calprotectin influences the aggregation of metal-free and metalbound amyloid-β by direct interaction†
  • Calciumdependent Tetramer Formation of S100A8 and S100A9 is Essential for Biological Activity .
  • Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson s disease
  • Applications of the European Parkinson s Disease Association sponsored Parkinson s Disease Composite Scale ( PDCS )
  • Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases
  • A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson s Disease
  • 9. Pfeiffer RF. Non-motor symptoms in Parkinsons disease. Parkinsonism & Related Disorders. 2016, 22: S119–S122.
    [2016]
  • 82. Toleikis Z, Ziaunys M, Baranauskiene L, Petrauskas V, Jaudzems K, Smirnovas V. S100A9 alters the pathway of alpha-synuclein amyloid aggregation. International Journal of Molecular Sciences. 2021, 22(15): 7972.
  • 81. Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinsons disease with the alpha-synuclein protein. Frontiers in Pharmacology. 2020, 11: 356.
    [2020]
  • 80. Franco-Iborra S, Cuadros T, Parent A, Romero-Gimenez J, Vila M, Perier C. Defective mitochondrial protein import contributes to complex I-induced mitochondrial dysfunction and neurodegeneration in Parkinsons disease. Cell Death & Disease. 2018, 9(11): 1–17.
    [2018]
  • 77. Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death & Differentiation. 2015, 22(3): 377–388.
    [2015]
  • 68. Ke Y, Dramiga J, Schütz U, Kril JJ, Ittner LM, Schröder H, et al. Tau- mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimers and Picks disease. PloS One. 2012, 7(4): e35678.
    [2012]
  • 67. Riku Y, Iwasaki Y, Ishigaki S, Akagi A, Hasegawa M, Nishioka K, et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain. 2022, awac091.
  • 63. Younas N, Zafar S, Shafiq M, Noor A, Siegert A, Arora AS, et al. SFPQ and Tau: critical factors contributing to rapid progression of Alzheimers disease. Acta Neuropathologica. 2020, 140(3): 317–339.
    [2020]
  • 61. Lu J, Shu R, Zhu Y. Dysregulation and dislocation of SFPQ disturbed DNA organization in Alzheimers disease and frontotemporal dementia. Journal of Alzheimers Disease. 2018, 61(4): 1311–1321.
    [2018]
  • 59. Pellarin I, DallAcqua A, Gambelli A, Pellizzari I, DAndrea S, Sonego M, et al. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene. 2020, 39(22): 4390–4403.
  • 58. Tsukahara T, Haniu H, Matsuda Y. PTB-Associated Splicing Factor (PSF) Is a PPARγ-Binding Protein and Growth Regulator of Colon Cancer Cells. PLOS ONE. 2013, 8(3): e58749.
    [2013]
  • 56. Shav-Tal Y, Lee BC, Bar-Haim S, Schori H, Zipori D. Reorganization of nuclear factors during myeloid differentiation. Journal of Cellular Biochemistry. 2001, 81(3): 379–392.
    [2001]
  • 55. Yarosh CA, Iacona JR, Lutz CS, Lynch KW. PSF: nuclear busy‐body or nuclear facilitator? Wiley Interdisciplinary Reviews: RNA. 2015, 6(4): 351–367.
    [2015]
  • 54. Shav-Tal Y, Zipori D. PSF and p54nrb/NonO – multi-functional nuclear proteins. FEBS Letters. 2002, 531(2): 109–114.
    [2002]
  • 53. Knott GJ, Bond CS, Fox AH. The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose molecular scaffold. Nucleic Acids Research. 2016, 44(9): 3989–4004.
    [2016]
  • 52. Mora Gallardo C, Sánchez de Diego A, Gutiérrez Hernández J, Talavera-Gutiérrez A, Fischer T, Martínez-A C, et al. Dido3-dependent SFPQ recruitment maintains efficiency in mammalian alternative splicing. Nucleic Acids Research. 2019, 47(10): 5381–5394.
    [2019]
  • 50. Lodeiro M, Puerta E, Ismail MAM, Rodriguez-Rodriguez P, Rönnbäck A, Codita A, et al. Aggregation of the Inflammatory S100A8 Precedes Aβ Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and Aβ Productions. The Journals of Gerontology: Series A. 2017, 72(3): 319–328.
    [2017]
  • 5. Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, et al. α- Synuclein in Parkinsons disease: causal or bystander? Journal of Neural Transmission. 2019, 126(7): 815–840.
    [2019]
  • 48. Wang C, Iashchishyn IA, Pansieri J, Nyström S, Klementieva O, Kara J, et al. S100A9-Driven Amyloid-Neuroinflammatory Cascade in Traumatic Brain Injury as a Precursor State for Alzheimers Disease. Scientific Reports. 2018, 8(1): 12836.
    [2018]
  • 46. Horvath I, Iashchishyn IA, Moskalenko RA, Wang C, Wärmländer SKTS, Wallin C, et al. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinsons disease: ex vivo and in vitro studies. Journal of Neuroinflammation. 2018, 15(1): 1–16.
    [2018]
  • 44. Wang C, Klechikov AG, Gharibyan AL, Wärmländer SKTS, Jarvet J, Zhao L, et al. The role of pro-inflammatory S100A9 in Alzheimers disease amyloid-neuroinflammatory cascade. Acta Neuropathologica. 2014, 127(4): 507–522.
    [2014]
  • 41. Vogl T, Leukert N, Barczyk K, Strupat K, Roth J. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2006, 1763(11): 1298–1306.
    [2006]
  • 39. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. The International Journal of Biochemistry & Cell Biology. 2001, 33(7): 637–668.
    [2001]
  • 38. Lee JS, Lee NR, Kashif A, Yang SJ, Nam AR, Song IC, et al. S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells. Frontiers in Immunology. 2020, 11.
  • 36. Viemann D, Barczyk K, Vogl T, Fischer U, Sunderkötter C, Schulze- Osthoff K, et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood. 2006, 109(6): 2453–2460.
    [2006]
  • 32. Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Frontiers in Immunology. 2018, 9.
    [2018]
  • 31. Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2020, 1867(6): 118677.
    [2020]
  • 30. Rezvanpour A, Shaw GS. Unique S100 target protein interactions. Gen Physiol Biophys. 2009, 28(Focus Issue): F39–F46.
    [2009]
  • 29. Cristóvão JS, Gomes CM. S100 proteins in Alzheimers disease. Frontiers in Neuroscience. 2019, 13: 463.
    [2019]
  • 28. Brás IC, Outeiro TF. Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. Cells. 2021, 10(2).
  • 25. Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology. 2022, 1–17.
  • 22. Zaman V, Shields DC, Shams R, Drasites KP, Matzelle D, Haque A, et al. Cellular and molecular pathophysiology in the progression of Parkinsons disease. Metabolic Brain Disease. 2021, 36(5): 815–827.
  • 21. Pajares M, I. Rojo A, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinsons Disease: Mechanisms and Therapeutic Implications. Cells. 2020, 9(7): 1687.
    [2020]
  • 2. Tysnes OB, Storstein A. Epidemiology of Parkinsons disease. Journal of Neural Transmission. 2017, 124(8): 901–905.
    [2017]
  • 19. Larsen SB, Hanss Z, Krüger R. The genetic architecture of mitochondrial dysfunction in Parkinsons disease. Cell and Tissue Research. 2018, 373(1): 21–37.
    [2018]
  • 17. Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinsons disease–lessons and emerging principles. Molecular Neurodegeneration. 2019, 14(1): 1–14.
    [2019]
  • 14. Yu E, Rudakou U, Krohn L, Mufti K, Ruskey JA, Asayesh F, et al. Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinsons Disease. Movement Disorders. 2021, 36(1): 178–187.
  • 1. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinsons disease: a systematic review and meta‐analysis. Movement Disorders. 2014, 29(13): 1583–1590.
    [2014]